Servier Singled Out for New EU Antitrust Investigation

Article

08 July 2009

As well as the reprimands and warnings from the European Commission's much anticipated report on its Big Pharma antitrust investigations on Wednesday was the announcement that the EC is launching a new investigation into Servier. The regulators are accusing the private-held French company of hindering the launch of generic versions of its heart disease drug, perindopril, saying they suspect that the company did deals with generic rivals Krka, Lupin, Matrix, Niche Generics Ltd and Teva to hold back cheaper versions.

Recent Videos
Arda Ural
Lynlee Brown
Arda Ural
Related Content
Justin Holko

A Global Approach to Oncology: Q&A with Justin Holko

Mike Hollan
April 28th 2025
Article

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.

Bill Coyle

Predicting and Planning for Tariff Impacts: Q&A with Bill Coyle

Mike Hollan
April 25th 2025
Article

The chaotic tariff situation is forcing pharma companies to prepare for multiple outcomes.

Marcel Botha

The Risks and Opportunities of Tariffs: Q&A with Marcel Botha

Mike Hollan
April 25th 2025
Article

While supply chain interruptions are a strong possibility, the tariffs also provide the industry with a chance to improve certain conditions.

Bringing Biotech Innovation Across Borders

Bringing Biotech Innovation Across Borders

Ed Ahn
April 17th 2025
Article

Four tips for midsized companies when entering new global markets.

Stock.adobe.com

ABPI Restores Novo Nordisk’s Membership

Mike Hollan
March 21st 2025
Article

The pharmaceutical company had previously been subjected to a 2-year suspension.

Mike Ryan

The Challenges of Market Access in Europe that Pharma Companies Face: Q&A with Mike Ryan

Mike Hollan
March 20th 2025
Article

Pharma companies face unique challenges with market access in this region.